Ketamine & Phencyclidine (PCP)
Ketamine, known both as a medical anesthetic and a psychoactive substance, operates through several mechanisms in the brain, impacting various neurotransmitter systems. Ketamine primarily acts as an antagonist at NMDA (N-methyl-D-aspartate) receptors in the brain. By blocking these receptors, Ketamine reduces the effects of glutamate, the primary excitatory neurotransmitter in the central nervous system. This leads to a decrease in neuronal activation and excitability, which is central to its anesthetic and dissociative effects.
Ketamine also has been found to interact with monoamine neurotransmitters like dopamine and serotonin, although these effects are less direct than its action on NMDA receptors. These interactions contribute to mood elevation and antidepressant effects. There is evidence suggesting that Ketamine may interact with opioid receptors, contributing to its analgesic (pain-relieving) properties.
Phencyclidine (PCP), originally developed as an anesthetic medication, is now known more widely as a recreational drug due to its profound psychoactive effects. PCP's primary mechanism of action is as a non-competitive antagonist of the NMDA (N-methyl-D-aspartate) receptor, a type of glutamate receptor. Like Ketamine PCP inhibits these receptors and decreases the activity of glutamate, leading to altered perceptions, hallucinations, and dissociative states. This is due to the reduced excitatory signaling in the brain.
PCP is known to inhibit the reuptake of dopamine, a neurotransmitter associated with mood, motivation, and reward. This increases dopamine levels in the brain and contributes to the mood-altering effects of PCP.
The increase in dopamine can lead to stimulant-like effects, such as increased energy and euphoria.
PCP also acts as an agonist at sigma-1 receptors, which may contribute to its hallucinogenic and psychotomimetic effects. PCP can alter acetylcholine neurotransmission, impacting memory and cognitive functions. There's evidence suggesting some interaction with opioid receptors, but this is not the primary mode of action.
PCP's complex interaction with multiple neurotransmitter systems in the brain underlies its potent psychoactive effects.
When combined, Ketamine and PCP can unpredictably amplify each other's effects. The NMDA antagonism can become more profound, leading to a deeper state of dissociation. The combined impact on dopamine and serotonin systems can lead to intense psychological effects, including hallucinations and potentially dangerous behavior alterations.
Side Effects and Dangers:
- Psychological Effects: Hallucinations, delusions, severe dissociation, and loss of reality, psychosis.
- Physical Risks: Elevated heart rate and blood pressure, respiratory depression, potential neurotoxicity, vomiting.
- Behavioral Changes: Disinhibition, aggressive behavior, and impaired judgment are common.
- Addiction and Dependence: Both substances have abuse potential, with PCP being particularly notorious for its addictive properties.
Ketamine and PCP are both dissociatives, but they have distinct pharmacological profiles and effects. Combining these substances can be extremely dangerous due to their potent and unpredictable synergistic effects. It can lead to severe physical and psychological outcomes, making it a highly unsafe practice.
All things considered, we recommend avoiding this combination under any conditions.
Last edited by a moderator: